



SMURF-Therapeutics, Inc. Announces Six New Appointments to Scientific Advisory Board

[Providence, Rhode Island, December 1, 2023] – SMURF-Therapeutics Company is pleased to introduce six accomplished professionals who have joined its esteemed Scientific Advisory Board, reinforcing its unwavering commitment to excellence and innovation in their respective fields. These appointments, personally selected by Wafik El-Deiry, MD, PhD, FACP, the Founder and CEO of SMURF-Therapeutics, mark a significant milestone in the company's pursuit of cutting-edge advancements.



J. Alan Diehl, PhD



Razelle Kurzrock, MD, FACP



Patrycja M. Dubielecka-Szczerba, PhD



Theresa M. Raimondo, PhD



Costas Koumenis, PhD



Ulrich Steidl, MD, PhD

The newly appointed members of the Scientific Advisory Boards include:

J. Alan Diehl, PhD: Dr. Diehl, a distinguished biochemist and cancer researcher, holds a prestigious tenured and endowed professorship at Case Western Reserve University. His primary focus centers on unraveling the intricate mechanisms of cancer progression, particularly on Mantel Cell Lymphoma that is driven by cyclin D.

Patrycja M. Dubielecka-Szczerba, PhD: Dr. Dubielecka-Szczerba, Associate Professor at Brown University, specializes in the biology of blood cancer-initiating stem cells. Her pioneering work targets neoplasm-initiating stem cells to effectively combat myeloproliferative neoplasms.

Costas Koumenis, PhD: Dr. Koumenis, the Richard Chamberlain Endowed Professor in the Department of Radiation Oncology at the University of Pennsylvania, is a world-renowned expert in the science of adaptation of tumor cells to stressful conditions within the tumor microenvironment. His research is at the forefront of Integrated Stress Response and innovations in radiation therapy.



Razelle Kurzrock, MD, FACP: Dr. Kurzrock's global recognition stems from her pivotal role as one of the foremost voices and accomplished investigators in the field of precision medicine. Leading the Early Therapeutics and Rare Cancers Committee (SWOG NCI), she has spearheaded over 100 early-phase clinical trials, contributing significantly to FDA drug approvals.

Theresa M. Raimondo, PhD: Dr. Raimondo, Assistant Professor⁴ at Brown University, has been conducting groundbreaking research on RNA therapeutics and drug delivery vectors, with transformative applications spanning immunotherapy, tissue regeneration, oncology, and gene editing. Her work holds immense potential for revolutionizing cancer treatment and tissue regeneration.

Ulrich Steidl, MD, PhD: As Professor and Chair at the Albert Einstein College of Medicine, Dr. Steidl has forged a path in molecular and mechanistic studies of pre-cancerous and leukemia stem cells. His research portfolio boasts high-profile publications, patents, and clinical trials.

"We are delighted to warmly welcome the distinguished professionals as they join our Scientific Advisory Board," expressed Wafik El-Deiry, MD, PhD, FACP, CEO of SMURF-Therapeutics. "Their wealth of knowledge and expertise will undoubtedly play a pivotal role in advancing our company's mission and driving innovation in the fields of anemia, oncology, and other potential new indications under consideration."

Complete bios of these new appointees are available on the SMURF-Therapeutics Company website.

These appointments underline SMURF-Therapeutics' steadfast dedication to the highest scientific standards and innovation to maintain a leading position in the translational medicine and oncology fields. The company strives to foster productive collaborations with prominent academic and industry experts. The invaluable insights contributed by these advisory board members will play a crucial role in guiding the company's research and development initiatives.

About SMURF-Therapeutics:

SMURF-Therapeutics is a pharmaceutical research and development company dedicated to advancing healthcare through cutting-edge drug discovery and clinical development. With a focus on oncology and other critical therapeutic areas, SMURF-Therapeutics is committed to developing innovative therapies that make a meaningful impact on patients' lives. The company is a start-up based on technology discovered by Dr. El-Deiry's laboratory at Brown University.